1. Home
  2. PBK vs NEUP Comparison

PBK vs NEUP Comparison

Compare PBK & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PowerBank Corporation Common Stock

PBK

PowerBank Corporation Common Stock

N/A

Current Price

$0.28

Market Cap

24.3M

Sector

Utilities

ML Signal

N/A

Logo Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

N/A

Current Price

$3.51

Market Cap

20.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PBK
NEUP
Founded
2013
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Power Generation
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
20.6M
IPO Year
2024
2002

Fundamental Metrics

Financial Performance
Metric
PBK
NEUP
Price
$0.28
$3.51
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $4.00
N/A
AVG Volume (30 Days)
★ 672.6K
15.0K
Earning Date
09-28-2026
09-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,174,165.00
Revenue This Year
$171.32
N/A
Revenue Next Year
$40.20
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.26
$3.19
52 Week High
$0.86
$21.31

Technical Indicators

Market Signals
Indicator
PBK
NEUP
Relative Strength Index (RSI) 31.10 30.87
Support Level $0.26 $3.28
Resistance Level $0.50 $3.86
Average True Range (ATR) 0.02 0.08
MACD 0.01 -0.01
Stochastic Oscillator 11.31 9.68

Price Performance

Historical Comparison
PBK
NEUP

About PBK PowerBank Corporation Common Stock

PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: